Application to double unique study with Diamyd’s diabetes vaccine submitted to the Swedish MPA

The research group at Lund University, that runs DiAPREV-IT, a clinical study evaluating if the diabetes vaccine Diamyd® can prevent or delay the onset of type 1 diabetes in children at high risk of developing the disease, has applied to the Swedish Medical Products Agency to expand the study with an additional 50 children. The first part of the study, which also comprises 50 children, is fully recruited and results are expected in 2015.“To expand this unique study is important as the chance to demonstrate a statistically significant effect of Diamyd’s diabetes vaccine increases the more